Department of Urogynaecology, King's College Hospital, London, UK.
F1000Res. 2020 Sep 11;9. doi: 10.12688/f1000research.26607.1. eCollection 2020.
Overactive bladder syndrome (OAB) is defined as urinary urgency, usually accompanied by frequency and nocturia, with or without urgency incontinence, in the absence of urinary tract infection or other obvious pathology. In this review, we focus on recent advances in the management of OAB. We examine the evidence on the effect of anticholinergic load on OAB patients. Advances in medical treatment include a new beta-3 agonist, vibegron, which is thought to have fewer drug interactions than mirabegron. Treatment of genitourinary syndrome of the menopause with oestrogens and ospemifene have also shown promise for OAB. Botulinum toxin has been shown to be an effective treatment option. We discuss the new implantable neuromodulators that are on the market as well as selective bladder denervation and laser technology.
膀胱过度活动症（OAB）被定义为尿急，通常伴有尿频和夜尿，伴有或不伴有急迫性尿失禁，不存在尿路感染或其他明显的病理。在这篇综述中，我们重点关注 OAB 管理的最新进展。我们研究了抗胆碱能负荷对 OAB 患者的影响的证据。医学治疗的进展包括一种新型β-3 激动剂维格列汀，它被认为比米拉贝隆更少发生药物相互作用。雌激素和奥昔布芬治疗女性生殖泌尿道综合征也为 OAB 带来了希望。肉毒杆菌毒素已被证明是一种有效的治疗选择。我们讨论了市场上的新型可植入神经调节剂以及选择性膀胱去神经支配和激光技术。
